サマリー

中東・アフリカの動物・ヒト用ワクチン市場は、2023年の3,480,103.5千米ドルから2031年には5,358,452.8千米ドルに達すると予測され、2024年から2031年の予測期間において年平均成長率5.6%で成長すると予測される。
市場区分
ガーナ、モザンビーク、ウガンダ、コンゴ民主共和国、スーダン、モロッコアンゴラマダガスカルマラウイザンビアコートジボワール、カメルーン、ジンバブエ、リビア、チャド、ボツワナ、ナミビア、レソト、モーリシャス、エスワティニ、コモロ、セイシェル、その他アフリカサウジアラビア、エジプト、U.A.E、イスラエル, イラン, イラク, オマーン, クウェート, カタール, バーレーン, イエメン, ヨルダン, レバノン, パレスチナ, その他の中東地域) - 2031年までの産業動向と予測

中東およびアフリカの動物用およびヒト用ワクチン市場のダイナミクス概観

推進要因
- 予防接種プログラムおよびキャンペーンの拡大
抑制要因

- 登録ワクチンの市場への供給不足

機会

- 市場プレーヤーによる戦略的着手と決定

市場プレイヤー

中東・アフリカの動物用・ヒト用ワクチン市場で事業を展開する主な市場参入企業は以下の通り：

- GSK plc.
- メルク社
- サノフィ
- ベーリンガーインゲルハイム・インターナショナルGmbH
- セバ
- OBP
- M.C.Iサンテアニマル
- バイオジェネシスバゴー
- ヘスターバイオサイエンスリミテッド

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 49
1.1 OBJECTIVES OF THE STUDY 49
1.2 MARKET DEFINITION 49
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET 49
1.4 LIMITATIONS 50
1.5 MARKETS COVERED 51
2 MARKET SEGMENTATION 53
2.1 MARKETS COVERED 53
2.2 GEOGRAPHICAL SCOPE 54
2.3 YEARS CONSIDERED FOR THE STUDY 54
2.4 CURRENCY AND PRICING 54
2.5 DBMR TRIPOD DATA VALIDATION MODEL 55
2.6 MULTIVARIATE MODELLING 58
2.7 TYPE LIFELINE CURVE 58
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 59
2.9 DBMR MARKET POSITION GRID 60
2.10 VENDOR SHARE ANALYSIS 61
2.11 SECONDARY SOURCES 62
2.12 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 65
4.1 PESTEL ANALYSIS 66
4.2 PORTER’S FIVE FORCES 67
5 REGULATORY SCENARIO 68
6 MARKET OVERVIEW 71
6.1 DRIVERS 73
6.1.1 GROWING IMMUNIZATION PROGRAMS AND CAMPAIGNS 73
6.1.2 GROWING PREVALENCE OF CHRONIC CONDITIONS 74
6.1.3 PRODUCTION OF NEW VACCINES IN THE HEALTHCARE MARKET 74
6.1.4 INCREASING GOVERNMENT SUPPORT AND FUNDING 75
6.2 RESTRAINTS 76
6.2.1 UNAVAILABILITY OF REGISTERED VACCINES IN THE MARKET 76
6.2.2 HIGH COST AND DIFFERENCES IN PRICING OF THE VACCINES 76
 
6.3 OPPORTUNITIES 77
6.3.1 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS 77
6.3.2 RISING PREVALENCE OF PIPELINE PRODUCTS 78
6.3.3 EMPHASIZING THE ROLE OF VACCINATION IN INDIVIDUAL AND COMMUNITY 79
6.4 CHALLENGES 81
6.4.1 HARMFUL SIDE EFFECTS CAUSED BY VACCINATION 81
6.4.2 FEAR AMONG PATIENTS RELATED TO INJECTIONS AND NEEDLE STICKS 82
7 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY TYPE 83
7.1 OVERVIEW 84
7.2 HUMAN 87
7.2.1 HUMAN PAPILLOMAVIRUS (HPV) 87
7.2.1.1 CERVICAL CANCER 88
7.2.1.2 OROPHARYNGEAL CANCER 88
7.2.1.3 ANAL CANCER 88
7.2.1.4 VULVAR AND VAGINAL CANCER 88
7.2.1.5 PENILE CANCER 88
7.2.1.6 OTHERS 88
7.2.2 PNEUMOCOCCAL VACCINE (PCV) 88
7.2.3 DTAP VACCINE 88
7.2.4 ROTAVIRUS VACCINE 88
7.2.5 INFLUENZA VACCINE 88
7.2.6 OTHERS 89
7.3 ANIMAL 89
7.3.1 BRUCELLOSIS 89
7.3.1.1 LIVE 90
7.3.1.2 INACTIVATED 90
7.3.1.2.1 CATTLE 90
7.3.1.2.2 CAPRINE 90
7.3.1.2.3 OVINE 90
7.3.2 FOOT AND MOUTH 91
7.3.2.1 INACTIVATED 91
7.3.2.2 LIVE 91
7.3.2.2.1 CATTLE 91
7.3.2.2.2 SHEEP AND GOAT 92
7.3.2.2.3 PIGS 92
7.3.2.2.4 OTHERS 92 
7.3.3 AFRICAN HORSE SICKNESS 92
7.3.3.1 LIVE 92
7.3.3.2 INACTIVATED 93
7.3.3.2.1 HORSE 93
7.3.3.2.2 DONKEY 93
7.3.3.2.3 MULES 93
7.3.4 RIFT VALLEY FEVER 94
7.3.4.1 LIVE 94
7.3.4.2 INACTIVATED 94
7.3.4.2.1 SMITHBURN STRAIN BASED VACCINE 94
7.3.4.2.2 ALUMINUM HYDROXIDE GEL AS ADJUVANT BASED VACCINE 95
7.3.4.2.3 Others 95
8 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY END USER 96
8.1 OVERVIEW 97
8.2 HOSPITAL 100
8.2.1 HUMAN HOSPITALS 100
8.2.2 VETERINARY HOSPITALS 100
8.3 CLINICS 100
8.3.1 SPECIALTY CLINICS 100
8.3.2 VETERINARY CLINICS 101
8.4 OTHERS 101
8.4.1 ANIMAL HUSBANDRY 101
8.4.2 PET SHOPS 101
8.4.3 OTHERS 101
9 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY DISTRIBUTION CHANNEL 102
9.1 OVERVIEW 103
9.2 DIRECT TENDERS 106
9.3 RETAIL SALES 106
9.4 OTHERS 106
10 MIDDLE EAST & AFRICA ANIMAL AND HUMAN VACCINES MARKET, BY COUNTRY 107
10.1 MIDDLE EAST & AFRICA 107
10.2 MIDDLE EAST 108
10.2.1 SAUDI ARABIA 116
10.2.2 EGYPT 122
10.2.3 U.A.E. 128
10.2.4 ISRAEL 134
10.2.5 IRAN 140
10.2.6 IRAQ 146
10.2.7 OMAN 152
10.2.8 KUWAIT 159
10.2.9 QATAR 166
10.2.10 BAHRAIN 172
10.2.11 YEMEN 178
10.2.12 JORDAN 185
10.2.13 LEBANON 191
10.2.14 PALESTINE 197
10.2.15 REST OF MIDDLE EAST 203 
10.3 AFRICA 204
10.3.1 SOUTH AFRICA 212
10.3.2 NIGERIA 218
10.3.3 ETHIOPIA 224
10.3.4 TANZANIA 231
10.3.5 KENYA 238
10.3.6 ALGERIA 244
10.3.7 GHANA 250
10.3.8 MOZAMBIQUE 257
10.3.9 UGANDA 264
10.3.10 DEMOCRATIC REPUBLIC OF CONGO 271
10.3.11 SUDAN 277
10.3.12 MOROCCO 284
10.3.13 ANGOLA 290
10.3.14 MADAGASCAR 297
10.3.15 MALAWI 304
10.3.16 ZAMBIA 311
10.3.17 IVORY COAST 317
10.3.18 CAMEROON 323
10.3.19 ZIMBABWE 329
10.3.20 LIBYA 335
10.3.21 CHAD 341
10.3.22 BOTSWANA 347
10.3.23 NAMIBIA 354
10.3.24 LESOTHO 361
10.3.25 MAURITIUS 367
10.3.26 ESWATINI 373
10.3.27 COMOROS 378
10.3.28 SEYCHELLES 384
10.3.29 REST OF AFRICA 390
11 MIDDLE EAST AND AFRICA ANIMAL AND HUMAN VACCINES MARKET, COMPANY LANDSCAPE 391
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 391
12 SWOT ANALYSIS 392 
13 COMPANY PROFILES 393
13.1 GSK PLC. 393
13.1.1 COMPANY SNAPSHOT 393
13.1.2 REVENUE ANALYSIS 393
13.1.3 PRODUCT PORTFOLIO 394
13.1.4 RECENT DEVELOPMENTS 395
13.2 MERCK & CO., INC. 398
13.2.1 COMPANY SNAPSHOT 398
13.2.2 REVENUE ANALYSIS 398
13.2.3 PRODUCT PORTFOLIO 399
13.2.4 RECENT DEVELOPMENTS 399
13.3 SANOFI 401
13.3.1 COMPANY SNAPSHOT 401
13.3.2 REVENUE ANALYSIS 401
13.3.3 PRODUCT PORTFOLIO 402
13.3.4 RECENT DEVELOPMENTS 403
13.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 404
13.4.1 COMPANY SNAPSHOT 404
13.4.2 PRODUCT PORTFOLIO 404
13.4.3 RECENT DEVELOPMENT 405
13.5 CEVA SANTÉ ANIMALE 406
13.5.1 COMPANY SNAPSHOT 406
13.5.2 PRODUCT PORTFOLIO 407
13.5.3 RECENT DEVELOPMENT 407
13.6 BIOGENESIS BAGO SA 408
13.6.1 COMPANY SNAPSHOT 408
13.6.2 PRODUCT PORTFOLIO 408
13.6.3 RECENT DEVELOPMENT 409
13.7 HESTER BIOSCIENCES LTD 410
13.7.1 COMPANY SNAPSHOT 410
13.7.2 REVENUE ANALYSIS 410
13.7.3 PRODUCT PORTFOLIO 411
13.7.4 RECENT DEVELOPMENT 411
13.8 M.C.I. SANTÉ ANIMALE 412
13.8.1 COMPANY SNAPSHOT 412
13.8.2 PRODUCT PORTFOLIO 412
13.8.3 RECENT DEVELOPMENT 412 
13.9 ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC (PYT) LTD 413
13.9.1 COMPANY SNAPSHOT 413
13.9.2 PRODUCT PORTFOLIO 413
13.9.3 RECENT DEVELOPMENTS 413
14 QUESTIONNAIRE 414
15 RELATED REPORTS 416